Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest of Maze Therapeutics, Inc. from 31 Mar 2024 to 31 Dec 2025
- Taxonomy & unit
- us-gaap: USD
- Description
- Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
- Summary
-
Maze Therapeutics, Inc. quarterly and annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD history and change rate from 31 Mar 2024 to 31 Dec 2025.
- Maze Therapeutics, Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending 31 Dec 2025 was $34,568,000, a 16% decline year-over-year.
- Maze Therapeutics, Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending 31 Dec 2025 was $131,120,000, a 346% decline year-over-year.
- Maze Therapeutics, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2025 was $131,120,000, a 346% decline from 2024.
- Source SEC data
- View on sec.gov
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Change (%)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Change (%)
Maze Therapeutics, Inc. Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)
| Period | TTM Value | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|---|
| Q4 2025 | $131,120,000 | $34,568,000 | -$4,714,000 | -16% | 01 Oct 2025 | 31 Dec 2025 | 10-K | 25 Mar 2026 | 2025 | FY |
| Q3 2025 | $126,406,000 | $30,087,000 | -$5,056,000 | -20% | 01 Jul 2025 | 30 Sep 2025 | 10-Q | 06 Nov 2025 | 2025 | Q3 |
| Q2 2025 | $121,350,000 | $33,679,000 | -$174,461,000 | -124% | 01 Apr 2025 | 30 Jun 2025 | 10-Q | 12 Aug 2025 | 2025 | Q2 |
| Q1 2025 | $53,111,000 | $32,786,000 | -$292,000 | -0.9% | 01 Jan 2025 | 31 Mar 2025 | 10-Q | 14 May 2025 | 2025 | Q1 |
| Q4 2024 | $53,403,000 | $29,854,000 | 01 Oct 2024 | 31 Dec 2024 | 10-K | 25 Mar 2026 | 2025 | FY | ||
| Q3 2024 | $25,031,000 | 01 Jul 2024 | 30 Sep 2024 | 10-Q | 06 Nov 2025 | 2025 | Q3 | |||
| Q2 2024 | $140,782,000 | 01 Apr 2024 | 30 Jun 2024 | 10-Q | 12 Aug 2025 | 2025 | Q2 | |||
| Q1 2024 | $32,494,000 | 01 Jan 2024 | 31 Mar 2024 | 10-Q | 14 May 2025 | 2025 | Q1 |
Maze Therapeutics, Inc. Annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)
| Period | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $131,120,000 | -$184,523,000 | -346% | 01 Jan 2025 | 31 Dec 2025 | 10-K | 25 Mar 2026 | 2025 | FY |
| 2024 | $53,403,000 | 01 Jan 2024 | 31 Dec 2024 | 10-K | 25 Mar 2026 | 2025 | FY |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.